Montelukast Intermediate Market Global Research Report - Forecast till 2027

Montelukast Intermediate Market: Information by Application (Asthma, Allergic Rhinitis, Bronchospasm and Urticaria) - Forecast till 2027

ID: MRFR/HC/6415-CR | May 2019 | Region: Bric | 78 pages

Montelukast Intermediate Market Overview


The Montelukast Intermediate Market is expected to grow at CAGR of 4.34% to reach USD 4,794.76 thousand till 2023.


Montelukast is a leukotriene receptor antagonist (LTRA) used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma. In addition, montelukast is indicated for the treatment of seasonal and perennial allergic rhinitis. Key factors driving the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration along with the increasing presence of generics. On the contrary, the presence of stringent regulatory policies and the high cost of manufacturing building blocks for active pharmaceutical ingredients are likely to hinder the market growth during the forecast period.


Market Dynamics


Factors characterizing the market growth are worldwide rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria, burgeoning pharmaceutical industry coupled with the increasing demand from API manufacturers, and montelukast patent expiration along with the increasing presence of generics. In 2016, asthma ranked twenty third (global) and thirty-first (in low- and middle-income countries — LMICs) among the leading causes of premature mortality (YLL). The World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide every year.


Montelukast Intermediate Market Revenue, by Application, 2017 (USD Mn)  Montelukast Intermediate Market_Image


Sources: MRFR Analysis


Segmentation


The montelukast intermediate Market, by application, can be classified into three types, namely, asthma, allergic rhinitis, bronchospasm, and urticaria.


Key Players


The prominent players in the Montelukast Intermediate market are VIVAN Life Sciences, P.G. Shah & Co., Manus Aktteva Biopharma LLP and Ortin Laboratories Limited.


Some of the key strategies followed by the players operating in the Montelukast Intermediate market were innovation, product development, acquisition, and expansion.


Montelukast Intermediate Market Share, by Region, 2017 (%)  Montelukast Intermediate Market_Image


Sources: MRFR Analysis


Regional Analysis


The Montelukast Intermediate Market in the Americas is segmented into North America and Latin America.


North America is expected to dominate the market. The market growth in this region is mainly due to the presence of giant pharmaceutical companies and sophisticated healthcare infrastructure and the rising prevalence of asthma and allergic rhinitis in the US and Canada. One in 13 people is living with asthma and is more common in adult women than adult men. Around six million children under the age of 18 have asthma being more common in children than adults. Therefore, the increasing burden of asthma is fueling the demand for montelukast and is assisting in market growth.


Europe currently holds a significant share in the Montelukast Intermediate market. The factors responsible for the market growth in this region are poor air quality due to high fuel emission is increasing the incidence of asthma, allergy, and chronic obstructive pulmonary disease (COPD) in the UK, Germany, and France. The European Respiratory Society reported that, currently, about 30 Million children and adults less than 45 years old have asthma within the UK and Ireland have some of the highest rates of asthma in the world. In Germany, there are an estimated 4 Million asthmatics. In addition, an article published in the NCBI journal stated that the prevalence of allergic diseases in Europe is high.


Asia-Pacific is expected to represent a promising outlook over the forecast period due to the growing geriatric population along with the rising prevalence of respiratory diseases. According to the WHO, currently, there are about 3 Million asthmatics in Japan of whom 7% have severe, and 30% have moderate asthma. In Australia, one child out of six under the age of 16 is affected by asthma, while, India has an estimated 15 to 20 Million.


The Middle East and Africa market are projected to hold the least share in the Montelukast Intermediate market. In this region, the Middle East is anticipated to dominate owing to the presence of countries such as Egypt, Saudi Arabia, and others.


Market Segmentation


Montelukast Intermediate Market, by Application



  • Asthma

  • Allergic Rhinitis

  • Bronchospasm

  • Urticaria


Montelukast Intermediate Market, by Region



  • North America


    • US

    • Canada




  • Europe


    • Germany

    • Russia

    • France

    • Italy

    • UK

    • Rest of Europe




  • Asia-Pacific


    • China

    • India

    • Japan

    • Rest of Asia-Pacific




  • Latin America


    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America




  • Middle East & Africa


Available Additional Customizations


Intended Audience



  • Montelukast API Manufacturer

  • Academic and Research Institutes

  • Pharmaceutical Manufacturers

  • Reference Laboratories

  • Pharmaceutical Raw Materials Suppliers

  • Montelukast Intermediate Manufacturers

  • Market Research and Consulting Firms



Frequently Asked Questions (FAQ) :


The forecast period of (2018-2023) would see the Montelukast Intermediate Market grow with a CAGR of 4.34%.

The projected valuation of the Montelukast Intermediate Market is USD 4794.76 thousand.

The high cost of the process to manufacture building blocks can deter market growth.

The players are Manus Aktteva Biopharma LLP, P.G. Shah & Co., VIVAN Life Sciences, and Ortin Laboratories Limited.

The segments are bronchospasm, allergic rhinitis, asthma, and urticaria.

1 Executive Summary

1.1 Market Attractiveness Analysis 13

2 Market Introduction

2.1 Definition 15

2.2 Scope Of The Study 15

2.3 Assumptions 15

2.4 Market Structure 15

3 Research Methodology

3.1 Research Process 16

3.2 Primary Research 17

3.3 Secondary Research 18

3.4 Market Size Estimation 19

3.5 Forecast Model 19

4 Market Dynamics

4.1 Introduction 20

4.2 Drivers 21

4.2.1 Worldwide Rising Prevalence Of Asthma, Bronchospasm, Allergic Rhinitis, And Urticaria 21

4.2.2 Burgeoning Pharmaceutical Industry Coupled With The Growing Demand From API Manufacturers 21

4.2.3 Montelukast Patent Expiration Along With The Increasing Presence Of Generics 22

4.3 Restraints 22

4.3.1 Presence Of Stringent Regulatory Policies 22

4.3.2 High Cost Of Manufacturing Building Blocks For APIs 22

4.4 Opportunity 23

4.4.1 Ongoing Research And Development Activities 23

5 Market Factor Analysis

5.1 Value Chain Analysis 24

5.1.1 Raw Material Sourcing 25

5.1.2 Manufacturing 25

5.1.3 Distribution & Sales 25

5.1.4 End Users 25

5.2 Porter’s Five Forces Model 26

5.2.1 Threat Of New Entrants 26

5.2.2 Bargaining Power Of Suppliers 27

5.2.3 Bargaining Power Of Buyers 27

5.2.4 Threat Of Substitutes 27

5.2.5 Intensity Of Rivalry 27

5.3 Investment Opportunities 28

5.4 Pricing Analysis 28

5.5 Clinical Trials 28

5.5.1 Overview 28

5.6 Patent Analysis 32

5.7 Regulatory Scenario 33

6 Montelukast Intermediate Market, By Application

6.1 Overview 34

6.2 Asthma 37

6.3 Allergic Rhinitis 38

6.4 Bronchospasm 39

6.5 Urticaria 40

7 Global Montelukast Intermediate Market, By Region

7.1 Overview 41

7.2 Americas 43

Montelukast Intermediate Market, By Application

7.2.1 North America 45

Montelukast Intermediate Market, By Application

7.2.1.1 US 46

Montelukast Intermediate Market, By Application

7.2.1.2 Canada 46

Montelukast Intermediate Market, By Application

7.2.2 Latin America 47

Montelukast Intermediate Market, By Application

7.3 Europe 48

Montelukast Intermediate Market, By Application

7.3.1 Western Europe 50

Montelukast Intermediate Market, By Application

7.3.1.1 UK 51

Montelukast Intermediate Market, By Application

7.3.1.2 France 51

Montelukast Intermediate Market, By Application

7.3.1.3 Spain 52

Montelukast Intermediate Market, By Application

7.3.1.4 Germany 52

Montelukast Intermediate Market, By Application

7.3.1.5 Italy 53

Montelukast Intermediate Market, By Application

7.3.1.6 Rest Of Western Europe 53

Montelukast Intermediate Market, By Application

7.3.2 Eastern Europe 54

Montelukast Intermediate Market, By Application

7.4 Asia-Pacific 55

Montelukast Intermediate Market, By Application

7.4.1 China 57

Montelukast Intermediate Market, By Application

7.4.2 India 57

Montelukast Intermediate Market, By Application

7.4.3 Japan 58

Montelukast Intermediate Market, By Application

7.4.4 Rest Of Asia-Pacific 58

Montelukast Intermediate Market, By Application

7.5 Middle East & Africa 59

Montelukast Intermediate Market, By Application

7.5.1 Middle East 61

Montelukast Intermediate Market, By Application

7.5.2 Africa 61

Montelukast Intermediate Market, By Application

8 Competitive Landscape

8.1 Introduction 62

8.2 Major Players In The Global Montelukast Intermediate Market 62

9 Company Profiles

9.1 VIVAN Life Sciences 63

9.1.1 Financial Overview 63

9.1.2 Products/Services Offered 63

9.1.3 Key Developments 63

9.1.4 SWOT Analysis 64

9.1.5 Key Strategies 64

9.2 P.G. Shah & Co. 65

9.2.1 Company Overview 65

9.2.2 Financial Overview 65

9.2.3 Products/Services Offered 65

9.2.4 Key Developments 65

9.2.5 SWOT Analysis 65

9.2.6 Key Strategies 66

9.3 Manus Aktteva Biopharma LLP 67

9.3.1 Company Overview 67

9.3.2 Financial Overview 67

9.3.3 Products/Services Offered 67

9.3.4 Key Developments 67

9.3.5 SWOT Analysis 67

9.3.6 Key Strategies 68

9.4 Ortin Laboratories Limited 69

9.4.1 Company Overview 69

9.4.2 Financial Overview 69

9.4.3 Products/Services Offered 69

9.4.4 Key Developments 69

9.4.5 SWOT Analysis 70

9.4.6 Key Strategies 70

10 Appendix

10.1 References 71

10.2 Related Reports 71

11 List Of Tables

TABLE 1 CLINICAL TRIALS 28

TABLE 2 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 35

TABLE 3 GLOBAL MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2020–2027 (KG) 36

TABLE 4 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR ASTHMA, BY REGION, 2020–2027 (USD THOUSAND) 37

TABLE 5 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR ALLERGIC RHINITIS, BY REGION, 2020–2027 (USD THOUSAND) 38

TABLE 6 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR BRONCHOSPASM, BY REGION, 2020–2027 (USD THOUSAND) 39

TABLE 7 GLOBAL MONTELUKAST INTERMEDIATE MARKET, FOR URTICARIA, BY REGION, 2020–2027 (USD THOUSAND) 40

TABLE 8 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2020–2027 (USD THOUSAND) 42

TABLE 9 AMERICAS: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2020–2027 (USD THOUSAND) 43

TABLE 10 AMERICAS: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 44

TABLE 11 AMERICAS: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2020–2027 (KG) 44

TABLE 12 NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 45

TABLE 13 NORTH AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 45

TABLE 14 US: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 46

TABLE 15 CANADA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 46

TABLE 16 LATIN AMERICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 47

TABLE 17 EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2020–2027 (USD THOUSAND) 48

TABLE 18 EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 49

TABLE 19 EUROPE: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2020–2027 (KG) 49

TABLE 20 WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 50

TABLE 21 WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 50

TABLE 22 UK: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 51

TABLE 23 FRANCE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 51

TABLE 24 SPAIN: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 52

TABLE 25 GERMANY: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 52

TABLE 26 ITALY: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 53

TABLE 27 REST OF WESTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 53

TABLE 28 EASTERN EUROPE: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 54

TABLE 29 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 55

TABLE 30 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 56

TABLE 31 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2020–2027 (KG) 56

TABLE 32 CHINA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 57

TABLE 33 INDIA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 57

TABLE 34 JAPAN: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 58

TABLE 35 REST OF ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 58

TABLE 36 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2020–2027 (USD THOUSAND) 59

TABLE 37 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 60

TABLE 38 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET VOLUME, BY APPLICATION, 2020–2027 (KG) 60

TABLE 39 MIDDLE EAST: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 61

TABLE 40 MIDDLE EAST: MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSAND) 61

12 List Of Figures

FIGURE 1 MARKET SYNOPSIS 12

FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL MONTELUKAST INTERMEDIATE MARKET 13

FIGURE 3 GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY APPLICATION, 2027 (%) 13

FIGURE 4 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020–2027 (USD THOUSANDS) 14

FIGURE 5 GLOBAL MONTELUKAST INTERMEDIATE MARKET: MARKET STRUCTURE 15

FIGURE 6 RESEARCH PROCESS OF MRFR 16

FIGURE 7 TOP-DOWN & BOTTOM-UP APPROACH 19

FIGURE 8 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL MONTELUKAST INTERMEDIATE MARKET 20

FIGURE 9 VALUE CHAIN: GLOBAL MONTELUKAST INTERMEDIATE MARKET 24

FIGURE 10 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL MONTELUKAST INTERMEDIATE MARKET 26

FIGURE 11 GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY APPLICATION, 2027 (%) 34

FIGURE 12 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY APPLICATION, 2020 & 2027 (USD THOUSAND) 35

FIGURE 13 GLOBAL MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2027 (%) 41

FIGURE 14 GLOBAL MONTELUKAST INTERMEDIATE MARKET, BY REGION, 2020 & 2027 (USD THOUSAND) 42

FIGURE 15 AMERICAS: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2027 (%) 43

FIGURE 16 EUROPE: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2027 (%) 48

FIGURE 17 ASIA-PACIFIC: MONTELUKAST INTERMEDIATE MARKET SHARE, BY COUNTRY, 2027 (%) 55

FIGURE 18 MIDDLE EAST & AFRICA: MONTELUKAST INTERMEDIATE MARKET SHARE, BY REGION, 2027 (%) 59



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.